Clinical Trial Detail

NCT ID NCT02960594
Title hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Inovio Pharmaceuticals
Indications

colorectal cancer

stomach cancer

breast carcinoma

lung carcinoma

ovarian carcinoma

esophageal cancer

head and neck squamous cell carcinoma

hepatocellular carcinoma

pancreatic carcinoma

Therapies

INO-1400 + INO-9012

INO-1400

Age Groups: adult senior

No variant requirements are available.